This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Renal disease				
Renal disease	Fibroblast growth factor 23 (FGF23)	<i>In vitro</i> and mouse studies suggest inhibiting FGF23 could help prevent left ventricular hypertrophy in chronic kidney disease (CKD). In CKD patients, high levels of FGF23 were associated with increased incidence of hypertrophy. In a rat model of CKD, an FGF receptor blocker decreased the incidence of hypertrophy compared with vehicle control. Next steps could include developing an FGF23 inhibitor. SciBX 4(42); doi:10.1038/scibx.2011.1189 Published online Oct. 27, 2011	Patent and licensing status unavailable	Faul, C. <i>et al.</i> <i>J. Clin. Invest.</i> ; published online Oct. 10, 2011; doi:10.1172/JCI46122 Contact: Myles Wolf, University of Miami Miller School of Medicine, Miami, Fla. e-mail: mwolf2@med.miami.edu Contact: Christian Faul, same affiliation as above e-mail: cfaul@med.miami.edu